What is Neurogastrx?
Founded in 2017, Neurogastrx operates at the intersection of biotechnology and gastroenterology. The company is dedicated to developing transformative therapies designed to address significant unmet medical needs in patients suffering from complex gastrointestinal disorders. By leveraging advanced pharmaceutical research, Neurogastrx aims to redefine the standard of care for GI-related conditions, moving beyond symptomatic management toward disease-modifying interventions.
The firm's market position is defined by its rigorous scientific methodology and its ability to attract top-tier life science investors. As a key player in the Massachusetts biotech ecosystem, Neurogastrx utilizes its strategic partnerships to bridge the gap between early-stage discovery and commercial-ready therapeutic solutions, ensuring that its pipeline remains competitive in a rapidly evolving healthcare market.
How much funding has Neurogastrx raised?
Neurogastrx has raised a total of $105M across 2 funding rounds:
Series A
$45M
Series B
$60M
Series A (2018): $45M with participation from venBio Partners, 5AM Ventures, and OrbiMed
Series B (2021): $60M led by RTW Investments, Samsara BioCapital, Vivo Capital, 5AM Ventures, and Marshall Wace
Key Investors in Neurogastrx
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
What's next for Neurogastrx?
With the recent capital infusion, Neurogastrx is poised to transition into a more mature phase of its corporate lifecycle. The strategic focus will likely shift toward scaling clinical operations and optimizing the development timeline for its lead assets. Investors are closely monitoring the company's ability to translate its research into tangible patient outcomes, which will be critical for future value creation.
The company's roadmap includes strengthening its intellectual property portfolio and potentially exploring collaborative opportunities to expand its therapeutic reach. As it moves forward, Neurogastrx remains a focal point for stakeholders interested in the intersection of gastrointestinal health and innovative drug development, with the current financing providing the necessary runway to achieve its long-term clinical objectives.
